MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC) | |
Im, S. -A.; Chow, L.; Shao, Z.; Tripathy, D.; Bardia, A.; Hurvitz, S.; Harbeck, N.; Colleoni, M.; Franke, F.; Germa, C. | |
2015 | |
卷号 | 26 |
会议录 | ANNALS OF ONCOLOGY
![]() |
语种 | 英语 |
URL标识 | 查看原文 |
ISSN号 | 0923-7534 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/4871636 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Im, S. -A.,Chow, L.,Shao, Z.,et al. MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC)[C]. 见:. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论